Juno Therapeutics Inc (JUNO)

27.66
NASDAQ : Health Care
Prev Close 27.66
Day Low/High 0.00 / 0.00
52 Wk Low/High 17.52 / 34.45
Avg Volume 1.83M
Exchange NASDAQ
Shares Outstanding 106.32M
Market Cap 3.02B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Juno Therapeutics Reports Second Quarter 2017 Financial Results

Juno Therapeutics Reports Second Quarter 2017 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the second quarter...

Juno Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3

Juno Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2017 on Thursday, August 3, 2017, after the close of U.

MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers

MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers

Here's what moving in the world of Biotech

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.

Biotech Stocks Showing Signs Of Resurgence

MarketNewsUpdates.com News Commentary

Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data At International Conference On Malignant Lymphoma

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented data from the TRANSCEND trial of JCAR017 in relapsed and...

Court Decides It Lacks Jurisdiction Before FDA Approval Occurs

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced today that the U.

Biotech Movers: NewLink, Inovio, Juno

Biotech Movers: NewLink, Inovio, Juno

NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Juno Therapeutics To Present At The Goldman Sachs 38th Annual Global Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Goldman Sachs 38 th Annual Global Healthcare Conference at 10:00 a.

Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates In Patients With Relapsed Or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated data from the TRANSCEND trial of JCAR017 in relapsed...

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.

Insiders Love Bioverativ, Juno Therapeutics and More

Insiders Love Bioverativ, Juno Therapeutics and More

Insiders at Bioverativ, Juno Therapeutics and three other companies have been buying up shares of their own stock recently.

JUNO: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and Juno Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.78 "days to cover" versus the median component at 4.71. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Juno Therapeutics Appoints Jay Flatley To Board Of Directors

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Jay Flatley to its Board of Directors.

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.

Juno Therapeutics To Present Key Clinical Data Updates On JCAR017 And JCAR014 At The 2017 American Society Of Clinical Oncology Annual Meeting

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with...

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

Juno Therapeutics To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2017 Health Care Conference at 3:40 p.

Kite Pharma Discloses CAR-T Patient Death, Rattling Investors

Kite Pharma Discloses CAR-T Patient Death, Rattling Investors

The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics.

Juno Therapeutics Reports First Quarter 2017 Financial Results

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the first quarter...

Nasdaq Nearing Overbought Status

Optical equipment maker Acacia isn't making higher highs; Juno Therapeutics is facing resistance.

Juno Therapeutics To Report First Quarter 2017 Financial Results On Thursday, May 4

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.

Juno Therapeutics Appoints Rupert Vessey To Board Of Directors

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr.

Juno Therapeutics Appoints Sunil Agarwal As President Of Research And Development

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.